PML risk stratification using anti-JCV antibody index and L-selectin

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

(2015) Luisa M. Villar et al.   ANNALS OF NEUROLOGY

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells

(2015) Michela Spadaro et al.   Journal of Neuroinflammation

Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients

(2015) Pabitra Basnyat et al.   Multiple Sclerosis and Related Disorders

Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection

(2014) Tilman Schneider-Hohendorf et al.   AIDS

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation

(2014) M. Capobianco et al.   EUROPEAN JOURNAL OF NEUROLOGY

MiR-126: a novel route for natalizumab action?

(2014) Maria Meira et al.   Multiple Sclerosis Journal

Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

(2014) Gary R Cutter et al.   Multiple Sclerosis Journal

Sorting out the risks in progressive multifocal leukoencephalopathy

(2014) Leonard H. Calabrese et al.   Nature Reviews Rheumatology

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

(2013) Peter Lee et al.   JOURNAL OF CLINICAL VIROLOGY

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

(2013) N. Schwab et al.   NEUROLOGY

Risk factors for rare diseases can be risky to define: PML and natalizumab

(2013) E. O. Major et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients

(2012) Diana V. Pastrana et al.   PLoS Pathogens

Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer

(2011) Diana V. Pastrana et al.   MEDICAL MICROBIOLOGY AND IMMUNOLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

(2010) Chen S Tan et al.   LANCET NEUROLOGY

BK virus antibody titers and intensity of infections after renal transplantation

(2008) Daniel L. Bohl et al.   JOURNAL OF CLINICAL VIROLOGY